Skip to main content

Table 2 Patient characteristics and the association with ACVR1B gene status

From: Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer

Patients characteristics

ACVR1B gene

P

 

Not deletion (n = 23)

Deletion (n = 6)

 

Age

   

<70 years

15

3

0.65

≥ 70 years

8

3

Gender

   

Male

12

3

1.00

Female

11

3

Primary size

   

<2 cm

18

5

1.00

≥2 cm

5

1

Lymph node metastasis

   

Negative

4

0

0.55

Positive

19

6

Distant metastasis

   

Negative

10

4

0.39

Positive

13

2

SMAD4 gene status

   

Not deletion

18

1

0.011*

Deletion

5

5

Treatment

   

Best supportive care

4

2

0.59

Chemotherapy

17

4

Unknown

2

0

 

Response to chemotherapy

   

PR

7

1

1.00

SD or PD

10

3

Median PFS (days)

252

167

0.89

Median OS (days)

344

215

0.66

  1. ACVR1B, activin receptor A, type IB; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free survival; OS, overall survival. PFS and OS were analyzed by log-rank test and the others by Fisher exact test.
  2. Legend: Six patients (6/29, 20.7%) had a deletion of ACVR1B gene, 10 patients (10/29, 34.5%) had a deletion of SMAD4 gene. Five of the 6 patients with a deletion of the ACVR1B gene also had a deletion of the SMAD4 gene (P = 0.011), but no significant differences in the other patient characteristics were observed between the two groups. Among 21 patients who received chemotherapy, no significant differences in PFS or OS were seen between the two groups.
Back to article page

Molecular Cancer

ISSN: 1476-4598